Fifth (5th) Training Programme for Qualified Persons for Pharmacovigilance (QPPV) and Symposium for Managers of the Local Pharmaceutical Industry
As part of its mandate to ensure Public Health and Safety, the Food and Drugs Authority (FDA) is organizing a Qualified Person in Pharmacovigilance (QPPV) training for stakeholders at the Fiesta Royale Hotel, Accra under the sponsorship of the UK Department for International Development (DFID).
The Nine (9) days long programme begun on the 25th of September, 2017 and will end with a Symposium on the 6th of October, 2017.
The 5th QPPV training programme is aimed at training thirty-four (34) representatives from the local pharmaceutical industry to be designated as QPPVs and also sensitize managers of the local pharmaceutical industry on the need to commit resources to pharmacovigilance and safety monitoring of marketed products.
The training would also ensure that representatives of medicine manufacturing and importing companies are trained to meet their legal obligations for the monitoring of the safety of their medicinal product on the market as specified in the Guideline on Good Pharmacovigilance Practices.
Opening the programme, the Ag. Chief Executive, Mrs. Delese Darko said patient safety has always been her passion and as CEO of the FDA, she would always work assiduously to make sure patients and public health is upheld and is of the highest standard and quality in the Country.
To emphasize her seriousness of ensuring public health and safety is of the highest standard in this country, the CEO said the Guest Speaker for the Symposium is Dr. June Raine who is the Director of Vigilance and Risk Management at the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom and the Chair of the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency. She is also a member of the WHO Advisory Committee on Safety of Medicinal Products
Participants are expected at the end of the program to be familiar with the roles and responsibilities of the QPPV; have an understanding of all relevant aspects of knowledge in pharmacovigilance required in order to take on the role of QPPV; set up and run an efficient pharmacovigilance system in Ghana and be able to compile regulatory documents (PSUR/PBRER and RMPs) as per the FDA’s requirements; understand how to monitor the performance and effectiveness of the pharmacovigilance system and its quality and appreciate the benefits of allocating resources to pharmacovigilance.